<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28471">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01977716</url>
  </required_header>
  <id_info>
    <org_study_id>R-2013-785-069</org_study_id>
    <nct_id>NCT01977716</nct_id>
  </id_info>
  <brief_title>Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients</brief_title>
  <official_title>The Role of Peritonitis in the Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <authority>Mexico: Coordinación de Investigación en Salud</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to analyze peritonitis rate and peritonitis bacteriology as risk
      factors for loss of residual renal function, technique failure and mortality in chronic
      kidney disease patients.

      Secondary objectives are: To know the current rate of peritonitis in peritoneal dialysis
      population and to understand the bacteriological profile of peritonitis.

      To know the rate and risk factors other than peritonitis involved in the loss of residual
      renal function.

      To analyze the utility of alternative diagnostic tests, such as reagent strips, for early
      detection of peritonitis when traditional tests are not available.

      To analyze the simultaneous measurement of serum creatinine and cystatin-C as alternative
      measurements of peritoneal clearance and residual renal function.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Loss of residual renal function</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Technique (peritoneal dialysis) failure</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Shift to hemodialysis</description>
  </primary_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>25 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Loss of Residual Renal Function</condition>
  <condition>Technique Failure in Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>Incident peritoneal dialysis patients</arm_group_label>
    <description>Patients with chronic kidney disease incident to peritoneal dialysis treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients starting PD as the first dialysis treatment will be considered. Recruitment
        will take place over a six-months period in hospitals belonging to the Instituto Mexicano
        de Seguro Social. Inclusion criteria include: adult patients with signed informed consent
        given; there should not be selection for age, gender, primary cause of renal disease.
        Patients will not be included if they were previously in hemodialysis or received renal
        transplant. Patients will also be excluded if they are on immunosuppressive therapy, have
        diagnosis of cancer, or are seropositive for HIV or hepatitis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion criteria include: adult patients with signed informed consent
        given; there should not be selection for age, gender, primary cause of renal disease.

        -

        Exclusion Criteria:Patients will not be included if they were previously in hemodialysis
        or received renal transplant. Patients will also be excluded if they are on
        immunosuppressive therapy, have diagnosis of cancer, or are seropositive for HIV or
        hepatitis.

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ramon Paniagua, MD, PhD</last_name>
    <phone>+52-55-56276900</phone>
    <phone_ext>21371</phone_ext>
    <email>jrpaniaguas@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unidad de Investigación Médica en Enfermedades Nefrológicas, Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>06722</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ramon Paniagua, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catarina Munguia-Miranda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria de Jesus Ventura-Garcia, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritonitis</keyword>
  <keyword>loss of residual renal function</keyword>
  <keyword>technique survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
